Company news
Genovis Ab (OMXSTO:GENO) news
Genovis Ab news releases on 6ix. Latest, Jul 23, 2026: Genovis AB Interim report January - June 2026
Press releases & updates
Genovis AB Interim report January - June 2026
July 23, 2026
Genovis Launches AlligBAITOR™ and Strengthens Its Offering in Advanced Protein Analytics
June 26, 2026
Genovis Acquires KPL — Expanding Its Enzyme Platform with a Proprietary Portfolio of Precision Proteases for Protein Analysis
June 1, 2026
Communiqué from Genovis AB (publ) Annual General Meeting May 18, 2026
May 18, 2026
Genovis Announces Change in Chief Financial Officer Position
May 12, 2026
Genovis AB Interim Report January-March 2026
April 28, 2026
Genovis AB publishes Annual Report 2025
April 23, 2026
Genovis : The board of directorsʼ proposal (genovis agm 2026 boarda proposals)
April 15, 2026
Genovis : Proxy form (genovis agm 2026 proxy form)
April 15, 2026
Genovis : Notice of AGM (genovis agm 2026 notice)
April 15, 2026
Genovis Enters Non-Exclusive License Agreement for EndoS2 Enzyme Technology for Antibody-Drug Conjugate (ADC) Development and Commercialization
March 25, 2026
Genovis : Nomination committee proposal (genovis agm 2026 nomination committee proposal)
March 11, 2026
Genovis AB Year-end Report January-December 2025
February 12, 2026
Genovis AB Interim report January-September 2025
November 7, 2025
Genovis receives order worth approximately 1 million euros from global pharmaceutical company
October 17, 2025
Genovis AB Half-Yearly report January – June 2025
August 12, 2025
Genovis Expands License Agreement to Access Proprietary Enzyme Technology for Therapeutic Antibody-Drug Conjugate Development
July 24, 2025
Genovis Exercises Call Option to Acquire Remaining Shares in SEQURNA, a fast-growing next-generation RNase inhibitors company
July 1, 2025